Showing recent highlights
What's New
PubMed · July 24, 2026
Researchers found that many people with heart failure struggle to take good care of themselves day-to-day — things like tracking symptoms, taking medications, and watching their diet — which can lead to more hospital stays and serious health problems. A study is testing whether receiving personalized text messages can help older adults with heart failure build better self-care habits, since texting is simpler and more accessible than many other digital health tools. This is early research and hasn't yet changed treatment guidelines.
Guidelines
ScienceDaily · July 22, 2026
A review by the American Heart Association found that up to 400 milligrams of caffeine a day — about three to five cups of regular black coffee — appears to be generally safe for the heart and may even be linked to lower chances of heart disease, stroke, and Type 2 diabetes. However, the source of caffeine matters a lot: highly concentrated energy drinks and shots were linked to raised blood pressure and irregular heartbeats, which can be dangerous. People with heart failure or other heart conditions may want to talk with their doctor before making changes to their caffeine habits.
What's New
PubMed · July 21, 2026
Researchers found that heart failure patients who took part in remote, virtual, or hybrid cardiac rehabilitation programs — supported by smartphone or digital health tools — showed slightly better improvements in exercise capacity compared to those who attended in-person rehabilitation programs. This matters because many people with heart failure struggle to get to a clinic regularly, and these findings suggest that doing rehab from home with digital support could be just as effective, or even a little better, at helping people get stronger and feel better. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 18, 2026
Researchers found that a new oral pill called AC01 may help the heart pump more effectively in people with heart failure where the heart muscle is weakened — without some of the dangerous side effects seen with older medications that do the same job. The drug works by making the heart muscle more sensitive to calcium, which helps it squeeze more strongly, and it also activates receptors in the body linked to the hormone ghrelin, which may offer additional benefits. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 16, 2026
Researchers found that smartphone and app-based tools that send people personalized nudges or tips at just the right moment — like when they're most likely to make a poor food choice — may help people eat healthier in their everyday lives. For someone managing obesity, this kind of real-time, tailored support could make it easier to build better habits without relying on memory or willpower alone. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 15, 2026
Researchers found that a diabetes medication like Ozempic or Victoza may work very differently depending on the type of heart failure a person has. In people with a type of heart failure where the heart muscle is stiff but still pumps normally (called HFpEF), these medications were linked to fewer hospitalizations, better exercise ability, and improved quality of life — but the benefits appeared much less clear in people whose heart pumps too weakly. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · July 14, 2026
A press release highlights a finding that exercise doesn't just make the heart stronger — it also changes the way the nerves controlling the heart work, almost like rewiring the system. For people with atrial fibrillation (an irregular heartbeat), this could be meaningful because those same nerves play a role in keeping the heart's rhythm steady. Researchers believe this discovery might one day help doctors tailor treatments more specifically to each person's heart condition.
What's New
JAMA · July 14, 2026
Researchers found that eating a lot of ultraprocessed foods — things like packaged snacks, fast food, and ready-made meals that are heavily manufactured and contain many added ingredients — may be linked to a higher risk of serious heart problems like heart attacks or strokes, as well as a greater chance of death overall. For people with type 2 diabetes, who are already at higher risk for heart-related complications, this connection could be especially important to be aware of. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 14, 2026
Researchers found that in people with heart failure who were holding onto excess fluid (a condition called congestion), two key factors — how well the kidneys were working and a chemical balance in the blood called bicarbonate levels — played a big role in how well water pills (diuretics) did their job of flushing out fluid. Specifically, patients whose kidneys were working a bit better responded more strongly to a combination of two water pills, furosemide and metolazone, compared to other combinations tested. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 10, 2026
Researchers found that people with heart failure who took both a diabetes medication like Ozempic or Victoza and a diabetes medication like Jardiance or Invokana together had lower rates of death, hospital stays, and worsening heart failure over one year compared to those who took only Jardiance or Invokana — and the combination also appeared to improve how well the heart was pumping without raising the risk of serious side effects. This is a meaningful finding because heart failure is a serious condition where the heart struggles to pump enough blood around the body, and having more treatment options that work well together could be important for patients and their doctors to know about. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 9, 2026
Researchers found that a diabetes medication like Jardiance or Invokana may offer meaningful benefits for older adults (65 and up) living with chronic kidney disease — a condition where the kidneys are damaged but not yet requiring dialysis. Specifically, people taking these medications had a lower risk of their kidney disease getting worse and a lower risk of serious heart problems like heart attacks or strokes, though they also had a higher chance of developing genital yeast infections as a side effect. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · July 7, 2026
A study found that nearly half of takeaway meals contained more salt than their menus claimed, with some single meals packing almost twice the amount of salt a person should have in an entire day. For people with high blood pressure — a condition where too much salt can make things worse by raising pressure in the blood vessels — this kind of hidden salt can be a real concern. This is early research and hasn't yet changed treatment guidelines.
What's New
JAMA · July 7, 2026
Researchers found that certain common food preservatives — ingredients added to packaged foods to keep them fresh longer — may be linked to high blood pressure and serious heart problems like heart attacks or strokes. This could matter for people with high blood pressure, since it suggests that everyday food choices, not just salt or fat, might play a role in heart health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 6, 2026
Researchers found that people living with heart failure — a condition where the heart can't pump blood as well as it should — often feel more supported and engaged in their own care when nurses guide them through digital health tools like apps or remote monitoring programs after leaving the hospital. The study explored what patients actually experienced, not just whether the tools "worked" on paper, finding that personal connection with a nurse and easy-to-use technology were key to whether people stuck with these programs. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 4, 2026
Researchers found that a heart failure medication called sacubitril/valsartan (brand name Entresto) may also help protect the kidneys in people with heart failure — reducing the risk of serious kidney decline by roughly 30% compared to other common heart medications. This matters because heart failure and kidney problems often go hand in hand, and a treatment that helps both at the same time could be meaningful for many patients. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
A study found that among people with a type of heart failure called heart failure with preserved ejection fraction — where the heart pumps normally but is too stiff to fill well — taking amlodipine (a common high blood pressure pill that relaxes blood vessels) lowered blood pressure slightly more than metoprolol (a beta-blocker that slows the heart), and also led to better exercise capacity and physical activity levels. Researchers also saw lower levels of a protein in the blood that signals heart strain, suggesting the heart may have been under less stress with amlodipine. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
A study found that using ultrasound to look at a large vein near the heart — called the inferior vena cava — may help doctors better manage fluid buildup in people hospitalized with heart failure, which is a condition where the heart struggles to pump blood effectively. This approach helped some patients leave the hospital sooner and, in one smaller study, dramatically reduced the risk of death compared to standard care alone. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that women with a type of heart failure called HFpEF — where the heart pumps normally but has trouble relaxing — had muscles that were about 40% less efficient at pulling oxygen out of the blood during exercise compared to men with the same condition. This matters because it helps explain why women with this condition often feel more short of breath and fatigued during physical activity, and it suggests that improving muscle health may be especially important for them. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that a diabetes medication like Jardiance or Invokana (specifically dapagliflozin) helped the body remove excess fluid just as well in heart failure patients with weaker kidneys as it did in those with stronger kidney function — which was a surprise, since the drug's fluid-removing effect was expected to fade as kidney function declined. Even more reassuring, starting the medication early during a heart failure hospital stay did not appear to harm kidney function. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that a common type of heart medication called beta-blockers — which slow the heart rate and reduce its workload — may be linked to a lower risk of death in people with a type of heart failure called heart failure with preserved ejection fraction, where the heart pumps normally but is too stiff to fill properly. Looking at data from over 440,000 patients across 13 studies, researchers also saw hints that beta-blockers might reduce the chances of being hospitalized for heart failure, though that finding was less consistent. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
A study found that a simple breathing and relaxation method called the Benson relaxation technique — which involves slow, focused breathing paired with a calming word or phrase — helped reduce anxiety in people with heart conditions. Researchers combined results from 8 smaller studies involving 538 patients and found a meaningful drop in anxiety scores, along with some improvements in heart rate and blood pressure. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that in people hospitalized with a sudden worsening of heart failure, some patients' bodies don't respond well to water pills (diuretics) — meaning the kidneys don't flush out enough salt and fluid, which is a sign of what doctors call 'diuretic resistance.' The study looked at whether a personalized approach to adjusting water pill doses based on how much salt was leaving the body in urine could still help these harder-to-treat patients, and found that this guided approach improved salt removal regardless of how resistant someone was to the medication — though it didn't clearly reduce the risk of death or being rehospitalized. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 30, 2026
Researchers found that using a small implanted heart monitor to detect early warning signs of worsening heart failure — and then having nurses adjust a patient's water pills based on those alerts — did not significantly improve outcomes compared to standard care, and the group receiving the extra interventions actually had numerically more serious heart problems, though the difference wasn't statistically definitive. The device itself appeared safe, with very few serious problems directly caused by the intervention. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 30, 2026
Researchers found that among people with heart failure who were monitored with a small implanted heart-rhythm tracker, a surprisingly high number — about two-thirds — developed atrial fibrillation (an irregular heartbeat) over three years, and many of these cases were newly detected. The study also looked at whether using the device's data to actively manage fluid buildup in the heart changed how often irregular heartbeats occurred, but it did not make a difference compared to standard care. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 30, 2026
Researchers found that a treatment called vagal nerve stimulation — which uses a small device to send gentle electrical signals through a nerve in the neck to help calm an overactive nervous system — showed some promising but not conclusive results for people with heart failure. The trial was stopped early by the company funding it (for reasons unrelated to whether the treatment was working or not), which meant there weren't enough patients enrolled to clearly prove whether it reduced serious heart problems like heart attacks or strokes, or the need for hospital stays. This is early research and hasn't yet changed treatment guidelines.
What's New
The Lancet · June 24, 2026
Researchers found that a drug targeting a hormone receptor called ghrelin — which plays a role in how the heart pumps — may help the heart squeeze more effectively in people with heart failure, meaning the heart isn't pumping as strongly as it should. This could matter because some people with advanced heart failure don't respond well enough to current treatments, so new options are needed. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 23, 2026
Researchers found that a blood pressure medication called sacubitril/valsartan helped people with a type of heart failure — where the heart pumps normally but is too stiff to fill properly — who also had a leaky heart valve (called mitral regurgitation, where a valve doesn't close fully and blood flows the wrong way). After six months, people taking this medication showed healthier heart pressure levels during exercise, were able to exercise better, and reported feeling noticeably better in their daily lives compared to those on standard care. This is early research and hasn't yet changed treatment guidelines.
What's New
JAMA · June 23, 2026
A study found that in people with heart failure with preserved ejection fraction (a type of heart failure where the heart still pumps, but doesn't fill or relax properly) who also have severe obesity, the individual muscle cells in the heart aren't contracting — or squeezing — as strongly as they should. This matters because it suggests that heart failure linked to severe obesity may involve a deeper problem at the cellular level, not just extra strain from weight alone, which could point researchers toward new ways of treating it. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 22, 2026
Researchers found that people with heart failure who used digital health tools to do cardiac rehabilitation at home — like guided exercise programs on apps or devices — were able to walk farther, breathe better during activity, and reported feeling better overall compared to those who didn't use these tools. Interestingly, people who used wearables (like fitness trackers) seemed to get the biggest boost in how far they could walk and how good they felt day-to-day, while those who used programs involving regular check-ins or coaching showed the strongest improvements in how efficiently their heart and lungs work together during exercise. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 16, 2026
Researchers found that an older heart medication called digitalis glycosides — which help the heart pump more effectively — may reduce the chances of serious heart-related complications in people with a type of heart failure where the heart muscle is weakened. Across more than 9,000 patients, those taking this medication were less likely to experience a worsening of their heart failure or die from a heart-related cause compared to those taking a placebo (an inactive pill). This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.